From: Salmonella blood stream infections in a tertiary care setting in Ghana
Antibiotics | Proportion of resistant Salmonella species (%) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | P-value | 2010 | 2011 | 2012 | 2013 | Correlation coefficient c,d | |||||||
TS a | NTS b | TS | NTS | TS | NTS | TS | NTS | TS | NTS | TS | NTS | ||
Ampicillin | 27/43 (62.7) | 81/103 (78.6) | 0.0466 | 12/14 (85.7) | 20/23 (83.3) | 9/13 (69.2) | 28/37 (75.6) | 3/13 (23.1) | 23/30 (76.6) | 3/10 (30.0) | 10/13 (76.9) | rs = −0.8, P = 0.2 | rs = −0.2, P = 0.8 |
cefuroxime | 11/63 (17.4) | 21/104 (20.2) | 0.6636 | 4/14 (28.5) | 5/20 (25.0)) | 4/13 (30.7) | 11/38 (28.9) | 2/26 (76.9) | 4/31 (12.9) | 1/10 (10.0) | 1/15 (66.7) | rs = −0.2, P = 0.8 | rs 0.4, P = 0.6 |
Cefotaxime | 0 | 6/99 (6.1) | - | 0 | 1/23 (4.5) | 0 | 3/41 (7.3) | 0 | 2/35 (57.1) | 0 | 0 | - | rs = −0.2, P = 0.8 |
Amoxicillin/ Clavulante | 1/12 (8.3) | 11/20 (55.5) | <0.01 | NT | 2/5 (40.0) | NT | 6/7 (85.7) | 1/12 (8.3) | 3/8 (37.5) | 0 | 0 | - | rs = −0.8, P = 0.2 |
Gentamicin | 1/24 (4.1) | 9/91 (9.9) | 0.3892 | 0 | 2/23 (9.1) | 0 | 5/35 (14.3) | 1/24 (4..2) | 2/33 (6.6) | 0 | 0 | rs = 0.26, P = 0.74 | rs = −0.8, P = 0.2 |
Amikacin | 1/11 (9.1) | 2/71 (2.8) | 0.3025 | 0 | 0 | 0 | 1/38 (2.6) | 0 | 1/33 (3.3) | 1/11 (9.1) | 0 | rs = 0.77, P = 0.23 | rs =0.26, P = 0.75 |
Chloramphenicol | 27/44 (61.4) | 66/90 (73.3) | 0.1579 | 10/13 (76.9) | 10/19 (52.6) | 12/13 (92.3) | 25/33 (75.7) | 5/18 (27.7) | 22/27 (81.5) | NT | 9/11 (81.8) | - | rs =1 P = 0.001 |
Cotrimoxazole | 24/174 (13.8) | 54/87 (65.5) | 0.0002 | 8/145 (5.5) | 10/18 (55.5) | 7/13 (53.8) | 19/36 (52.7) | 8/10 (80.0) | 17/21 (80.9) | 1/6 (16.7) | 8/12 (66.7) | rs =0.4, P = 0.6 | rs = 0.6, P = 0.4 |
Tetracycline | 26/37 (70.3) | 60/83 (72.3) | 0.8204 | 9/14 (64.2) | 14/17 (82.3) | 9/13 (69.2) | 22/32 (68.8) | 8/10 (80.0) | 16/23 (69.5) | 0 | 8/11 (72.7) | rs = −0.2, P = 0.8 | rs = −0.2, P = 0.8 |
Ciprofloxacin | 0 | 1/ 135 (0.7) | - | 0 | 0 | 0 | 1/135 (0.7) | 0 | 0 | 0 | 0 | - | - |